Noveris Health Sciences Launches Investor Website, Engages Fairfax Partners
VANCOUVER, BC — March 14, 2026 — Leads & Copy — Noveris Health Sciences Inc. has launched a new investor-facing website and engaged Fairfax Partners Inc. to provide investor relations and digital marketing services.
The website, found at http://noveris.health, aims to provide shareholders, prospective investors, and other stakeholders with access to corporate information, investor materials, and company updates.
The engagement with Fairfax Partners, headquartered in Vancouver, British Columbia, is effective as of March 13, 2026, for an initial term of three months. The total cost is up to CAD $150,000 plus applicable GST.
Fairfax Partners will provide services across four areas. FRAME, which includes communications infrastructure such as investor website development, CRM setup, and digital integration, will be provided complimentary. Post!, covering investor relations management, including drafting and disseminating investor updates, managing inbound communications, and disclosure support, is billed at CAD $3,999 per month. MyIR Pro, which manages the Company’s phone system and email inbox, CRM and communications management, and assignment of a dedicated Fair agent, is billed at CAD $1,195 per month. Fairfax+, which covers digital marketing campaign execution across Google, LinkedIn, and financial platforms, carries a budget of up to CAD $44,000 per month. Including any potential expenses, the engagement represents an aggregate of CAD $50,000 per month plus applicable GST.
According to Jason Birmingham, Chief Executive Officer, the launch of the new website and the engagement of Fairfax Partners reflects the company’s commitment to transparent communication and proactive outreach to current and prospective investors as Noveris continues to advance its business objectives.
It is disclosed that Fairfax Partners Inc. and its directors do not own, directly or indirectly, any shares in the capital of Noveris Health Sciences Inc. The Company will file all required regulatory disclosures in connection with this engagement in accordance with applicable securities laws.
Noveris Health Sciences Inc. is a publicly traded biopharmaceutical and life sciences company focused on the research, development, and commercialization of next-generation medications and therapies to address mental health disorders, including nicotine addiction and post-traumatic stress disorder (PTSD). The Company’s core strategy blends advanced drug chemistry with artificial intelligence (AI) and a robust infrastructure for drug discovery and development, leveraging pharma research capabilities at the University of Alberta to advance its pipeline of patent-pending second-generation compounds. Noveris serves scientific, medical, clinical, and veteran organizations worldwide and is working toward Health Canada and FDA regulatory approvals for its pipeline assets.
Source: Noveris Health Sciences Inc.
Share this story:
